Abstract:Introduction: The overexpression of ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2, are two of the major mediators of multidrug resistance (MDR) in cancers. Although multiple ABCB1 and ABCG2 inhibitors have been developed and some have undergone evaluation in clinical trials, none have been clinically approved. The compound, MK-2206, an inhibitor of the protein kinases AKT1/2/3, is undergoing evaluation in multiple clinical trials for the treatment of certain types of cancers, including those resistant to erlotinib. In this in vitro study, we conducted in vitro experiments to determine if MK-2206 attenuates multidrug resistance in cancer cells overexpressing the ABCB1 or ABCG2 transporter. Methodology: The efficacy of MK-2206 (0.03-1 μM), in combination with the ABCB1 transporter sub-strates doxorubicin and paclitaxel, and ABCG2 transporter substrates mitoxantrone, SN-38 and topotecan, were determined in the cancer cell lines, KB-C2 and SW620/Ad300, which overexpress the ABCB1 transporter or H460/MX20 and S1-M1-80, which overexpress the ABCG2 transporter, respectively. The expression level and the localization of ABCG2 transporter on the cancer cells membranes were determined using western blot and immunofluorescence assays, respectively, following the incubation of cells with MK-2206. Finally, the interaction between MK-2206 and human ABCG2 transporter was predicted using computer-aided molecular modeling. Results: MK-2206 significantly increased the efficacy of anticancer compounds that were substrates for the ABCG2 but not the ABCB1 transporter. MK-2206 alone (0.03-1 μM) did not significantly alter the viability of H460/MX20 and S1-M1-80 cancer cells, which overexpress the ABCG2 transporter, compared to cells incubated with vehicle. However, MK-2206 (0.3 and 1 μM) significantly increased the anticancer efficacy of mitoxantrone, SN-38 and topotecan, in H460/MX20 and S1-M1-80 cancer cells, as indicated by a significant decrease in their IC50 values, compared to cells incubated with vehicle. MK-2206 significantly increased the basal activity of the ABCG2 ATPase (EC50 = 0.46 μM) but did not significantly alter its expression level and sub-localization in the membrane. The molecular modeling results suggested that MK-2206 binds to the active pocket of the ABCG2 transporter, by a hydrogen bond, hydrophobic interactions and π-π stacking. Conclusion: These in vitro data indicated that MK-2206 surmounts resistance to mitoxantrone, SN-38 and topotecan in cancer cells overexpressing the ABCG2 transporter. If these results can be translated to humans, it is possible that MK-2206 could be used to surmount MDR in cancer cells overexpressing the ABCG2 transporter.

The Chk1 Inhibitor MK-8776 Increases the Radiosensitivity of Human Triple-Negative Breast Cancer by Inhibiting Autophagy.

AKT Inhibitor MK-2206 Sensitizes Breast Cancer Cells to MLN4924, a First-in-class NEDD8-activating Enzyme (NAE) Inhibitor

Nimotuzumab Abrogates Acquired Radioresistance of KYSE-150R Esophageal Cancer Cells by Inhibiting EGFR Signaling and Cellular DNA Repair

Combined Aurora Kinase A and CHK1 Inhibition enhances radiosensitivity of triple-negative breast cancer through induction of apoptosis and mitotic catastrophe associated with excessive DNA damage

The Cytoprotective Role Of Gemcitabine-Induced Autophagy Associated With Apoptosis Inhibition In Triple-Negative Mda-Mb-231 Breast Cancer Cells

The AKT inhibitor, MK-2206, attenuates ABCG2-mediated drug resistance in lung and colon cancer cells

The P21-Dependent Radiosensitization Of Human Breast Cancer Cells By Mln4924, An Investigational Inhibitor Of Nedd8 Activating Enzyme

Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin

Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235

Inhibition of DNA-PKcs Enhances Radiosensitivity and Increases the Levels of ATM and ATR in NSCLC Cells Exposed to Carbon Ion Irradiation.

One Therapeutic Approach for Triple-Negative Breast Cancer: Checkpoint Kinase 1 Inhibitor AZD7762 Combination with Neoadjuvant Carboplatin.

Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells

Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation

Niclosamide Sensitizes Triple-Negative Breast Cancer Cells to Ionizing Radiation in Association with the Inhibition of Wnt/β-catenin Signaling

Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy

Novel Amidine Derivative K1586 Sensitizes Colorectal Cancer Cells to Ionizing Radiation by Inducing Chk1 Instability

Building Radiation-Resistant Model in Triple-Negative Breast Cancer to Screen Radioresistance-Related Molecular Markers

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL

The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects Against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-dependent Autophagic, but Not Apoptotic Cell Death Pathway.

3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiation

MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB